Health-Related Quality of Life in Adrenocortical Carcinoma: Development of the Disease-Specific Questionnaire ACC-QOL and Results from the PROFILES Registry.
adrenocortical carcinoma
chemotherapy
health-related quality of life
mitotane
questionnaire development
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
08 Mar 2022
08 Mar 2022
Historique:
received:
11
01
2022
revised:
28
02
2022
accepted:
02
03
2022
entrez:
25
3
2022
pubmed:
26
3
2022
medline:
26
3
2022
Statut:
epublish
Résumé
We aimed to develop a disease-specific adrenocortical carcinoma (ACC) health-related quality of life (HRQoL) questionnaire (ACC-QOL) and assess HRQoL in a population-based cohort of patients with ACC. Development was in line with European Organization for Research and Treatment of Cancer (EORTC) guidelines, though not an EORTC product. In phase I and II, we identified 90 potential HRQoL issues using literature and focus groups, which were reduced to 39 by healthcare professionals. Pilot testing resulted in 28 questions, to be used alongside the EORTC QLQ-C30. In Phase III, 100 patients with ACC were asked to complete the questionnaires twice in the PROFILES registry (3-month interval, respondents: first 67, second 51). Confirmatory factor analysis demonstrated the structural validity of 26 questions with their scale structure (mitotane side-effects, hypercortisolism/hydrocortisone effects, emotional effects). Internal consistency and reliability were good (Cronbach's alpha 0.897, Interclass correlation coefficient 0.860). Responsiveness analysis showed good discriminative ability (AUC 0.788). Patients diagnosed more than 5 years ago reported a good HRQoL compared with the Dutch reference population, but experienced residual fatigue and emotional problems. Patients who underwent recent treatment reported a lower HRQoL and problems in several domains. In conclusion, we developed an ACC-specific HRQoL questionnaire with good psychometric properties.
Identifiants
pubmed: 35326518
pii: cancers14061366
doi: 10.3390/cancers14061366
pmc: PMC8946128
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
Cochrane Database Syst Rev. 2013 Mar 28;(3):CD007730
pubmed: 23543556
BMC Health Serv Res. 2013 Jun 11;13:211
pubmed: 23758898
J Endocr Soc. 2020 Apr 01;4(5):bvaa040
pubmed: 32342024
Health Qual Life Outcomes. 2009 Dec 23;7:102
pubmed: 20030832
Acta Oncol. 2018 Oct;57(10):1381-1391
pubmed: 29912607
Biometrics. 1977 Mar;33(1):159-74
pubmed: 843571
N Engl J Med. 2012 Jun 7;366(23):2189-97
pubmed: 22551107
J Adv Nurs. 2008 Apr;62(1):107-15
pubmed: 18352969
Curr Oncol Rep. 2017 Feb;19(2):12
pubmed: 28220450
J Clin Epidemiol. 2010 Jul;63(7):737-45
pubmed: 20494804
Eur J Cancer. 2013 Jul;49(11):2579-86
pubmed: 23561851
Cancers (Basel). 2019 Oct 08;11(10):
pubmed: 31597261
J Patient Rep Outcomes. 2018 Sep 15;2:42
pubmed: 30294712
Eur J Endocrinol. 2018 Oct 01;179(4):G1-G46
pubmed: 30299884
Eur J Cancer. 2011 Sep;47(14):2188-94
pubmed: 21621408
Ann Oncol. 2020 Nov;31(11):1476-1490
pubmed: 32861807
Eur J Cancer. 2002 Aug;38(12):1611-4
pubmed: 12142050